Mai Tanimura, Nobutaka Kataoka, Yusuke Kunimatsu, Rei Tsutsumi, Izumi Sato, Takayuki Nakano, Keiko Tanimura, Takayuki Takeda. Respirol Case Rep 2021
Times Cited: 1
Times Cited: 1
Times Cited
Times Co-cited
Similarity
Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
Kurtis D Davies, Sakshi Mahale, David P Astling, Dara L Aisner, Anh T Le, Trista K Hinz, Aria Vaishnavi, Paul A Bunn, Lynn E Heasley, Aik-Choon Tan,[...]. PLoS One 2013
Kurtis D Davies, Sakshi Mahale, David P Astling, Dara L Aisner, Anh T Le, Trista K Hinz, Aria Vaishnavi, Paul A Bunn, Lynn E Heasley, Aik-Choon Tan,[...]. PLoS One 2013
100
Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications.
Yuemin Bian, Xiang-Qun Sean Xie. AAPS J 2018
Yuemin Bian, Xiang-Qun Sean Xie. AAPS J 2018
100
Functional characterization of NTRK1 mutations identified in melanoma.
Claudia Miranda, Mara Mazzoni, Marialuisa Sensi, Marco A Pierotti, Angela Greco. Genes Chromosomes Cancer 2014
Claudia Miranda, Mara Mazzoni, Marialuisa Sensi, Marco A Pierotti, Angela Greco. Genes Chromosomes Cancer 2014
100
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
100
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Mariangela Russo, Sandra Misale, Ge Wei, Giulia Siravegna, Giovanni Crisafulli, Luca Lazzari, Giorgio Corti, Giuseppe Rospo, Luca Novara, Benedetta Mussolin,[...]. Cancer Discov 2016
Mariangela Russo, Sandra Misale, Ge Wei, Giulia Siravegna, Giovanni Crisafulli, Luca Lazzari, Giorgio Corti, Giuseppe Rospo, Luca Novara, Benedetta Mussolin,[...]. Cancer Discov 2016
100
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
100
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Helen Y Zou, Qiuhua Li, Lars D Engstrom, Melissa West, Vicky Appleman, Katy A Wong, Michele McTigue, Ya-Li Deng, Wei Liu, Alexei Brooun,[...]. Proc Natl Acad Sci U S A 2015
Helen Y Zou, Qiuhua Li, Lars D Engstrom, Melissa West, Vicky Appleman, Katy A Wong, Michele McTigue, Ya-Li Deng, Wei Liu, Alexei Brooun,[...]. Proc Natl Acad Sci U S A 2015
100
Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion.
Danielle B Dunn. J Adv Pract Oncol 2020
Danielle B Dunn. J Adv Pract Oncol 2020
100
TrkA overexpression enhances growth and metastasis of breast cancer cells.
C Lagadec, S Meignan, E Adriaenssens, B Foveau, E Vanhecke, R Romon, R-A Toillon, B Oxombre, H Hondermarck, X Le Bourhis. Oncogene 2009
C Lagadec, S Meignan, E Adriaenssens, B Foveau, E Vanhecke, R Romon, R-A Toillon, B Oxombre, H Hondermarck, X Le Bourhis. Oncogene 2009
100
Hit Triage and Validation in Phenotypic Screening: Considerations and Strategies.
Fabien Vincent, Paula M Loria, Andrea D Weston, Claire M Steppan, Regis Doyonnas, Yue-Ming Wang, Kristin L Rockwell, Marie-Claire Peakman. Cell Chem Biol 2020
Fabien Vincent, Paula M Loria, Andrea D Weston, Claire M Steppan, Regis Doyonnas, Yue-Ming Wang, Kristin L Rockwell, Marie-Claire Peakman. Cell Chem Biol 2020
100
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
100
Opportunities and challenges in phenotypic drug discovery: an industry perspective.
John G Moffat, Fabien Vincent, Jonathan A Lee, Jörg Eder, Marco Prunotto. Nat Rev Drug Discov 2017
John G Moffat, Fabien Vincent, Jonathan A Lee, Jörg Eder, Marco Prunotto. Nat Rev Drug Discov 2017
100
The trk proto-oncogene encodes a receptor for nerve growth factor.
R Klein, S Q Jing, V Nanduri, E O'Rourke, M Barbacid. Cell 1991
R Klein, S Q Jing, V Nanduri, E O'Rourke, M Barbacid. Cell 1991
100
Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia.
G W Reuther, Q T Lambert, M A Caligiuri, C J Der. Mol Cell Biol 2000
G W Reuther, Q T Lambert, M A Caligiuri, C J Der. Mol Cell Biol 2000
100
Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells.
Angelika Eggert, Michael A Grotzer, Naohiko Ikegaki, Xing-ge Liu, Audrey E Evans, Garrett M Brodeur. Cancer Res 2002
Angelika Eggert, Michael A Grotzer, Naohiko Ikegaki, Xing-ge Liu, Audrey E Evans, Garrett M Brodeur. Cancer Res 2002
100
Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target.
Anna Saborowski, Michael Saborowski, Monika A Davare, Brian J Druker, David S Klimstra, Scott W Lowe. Proc Natl Acad Sci U S A 2013
Anna Saborowski, Michael Saborowski, Monika A Davare, Brian J Druker, David S Klimstra, Scott W Lowe. Proc Natl Acad Sci U S A 2013
100
The anaplastic lymphoma kinase in the pathogenesis of cancer.
Roberto Chiarle, Claudia Voena, Chiara Ambrogio, Roberto Piva, Giorgio Inghirami. Nat Rev Cancer 2008
Roberto Chiarle, Claudia Voena, Chiara Ambrogio, Roberto Piva, Giorgio Inghirami. Nat Rev Cancer 2008
100
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Christian Rolfo, Rossana Ruiz, Elisa Giovannetti, Ignacio Gil-Bazo, Antonio Russo, Francesco Passiglia, Marco Giallombardo, Marc Peeters, Luis Raez. Expert Opin Investig Drugs 2015
Christian Rolfo, Rossana Ruiz, Elisa Giovannetti, Ignacio Gil-Bazo, Antonio Russo, Francesco Passiglia, Marco Giallombardo, Marc Peeters, Luis Raez. Expert Opin Investig Drugs 2015
100
Phenotypic screening: the future of antibody discovery.
Andrea L Gonzalez-Munoz, Ralph R Minter, Steven J Rust. Drug Discov Today 2016
Andrea L Gonzalez-Munoz, Ralph R Minter, Steven J Rust. Drug Discov Today 2016
100
Role and relevance of TrkB mutations and expression in non-small cell lung cancer.
Taishi Harada, Yasushi Yatabe, Masafumi Takeshita, Takaomi Koga, Tokujiro Yano, Yisong Wang, Giuseppe Giaccone. Clin Cancer Res 2011
Taishi Harada, Yasushi Yatabe, Masafumi Takeshita, Takaomi Koga, Tokujiro Yano, Yisong Wang, Giuseppe Giaccone. Clin Cancer Res 2011
100
Entrectinib-related myocarditis in a young female patient with metastatic non-small cell lung cancer.
Marta Fonseca, Daniel H Chen, John Malcolm Walker, Arjun K Ghosh. BMJ Case Rep 2021
Marta Fonseca, Daniel H Chen, John Malcolm Walker, Arjun K Ghosh. BMJ Case Rep 2021
100
trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3.
F Lamballe, R Klein, M Barbacid. Cell 1991
F Lamballe, R Klein, M Barbacid. Cell 1991
100
Inhibiting TRK Proteins in Clinical Cancer Therapy.
Allison M Lange, Hui-Wen Lo. Cancers (Basel) 2018
Allison M Lange, Hui-Wen Lo. Cancers (Basel) 2018
100
Cell and small animal models for phenotypic drug discovery.
Mihaly Szabo, Sara Svensson Akusjärvi, Ankur Saxena, Jianping Liu, Gayathri Chandrasekar, Satish S Kitambi. Drug Des Devel Ther 2017
Mihaly Szabo, Sara Svensson Akusjärvi, Ankur Saxena, Jianping Liu, Gayathri Chandrasekar, Satish S Kitambi. Drug Des Devel Ther 2017
100
ROS receptor tyrosine kinase: a new potential target for anticancer drugs.
Ibrahim Mustafa El-Deeb, Kyung Ho Yoo, So Ha Lee. Med Res Rev 2011
Ibrahim Mustafa El-Deeb, Kyung Ho Yoo, So Ha Lee. Med Res Rev 2011
100
Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism.
Seong-Wook Seo, Dong-Gyun Han, Eugene Choi, Taeuk Park, Jong Hyuk Byun, Hyun-Jong Cho, Il Hyo Jung, In-Soo Yoon. Biomed Pharmacother 2022
Seong-Wook Seo, Dong-Gyun Han, Eugene Choi, Taeuk Park, Jong Hyuk Byun, Hyun-Jong Cho, Il Hyo Jung, In-Soo Yoon. Biomed Pharmacother 2022
100
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
Dana S Neel, David V Allegakoen, Victor Olivas, Manasi K Mayekar, Golzar Hemmati, Nilanjana Chatterjee, Collin M Blakely, Caroline E McCoach, Julia K Rotow, Anh Le,[...]. Cancer Res 2019
Dana S Neel, David V Allegakoen, Victor Olivas, Manasi K Mayekar, Golzar Hemmati, Nilanjana Chatterjee, Collin M Blakely, Caroline E McCoach, Julia K Rotow, Anh Le,[...]. Cancer Res 2019
100
Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.
N Rajan, R Elliott, O Clewes, A Mackay, J S Reis-Filho, J Burn, J Langtry, M Sieber-Blum, C J Lord, A Ashworth. Oncogene 2011
N Rajan, R Elliott, O Clewes, A Mackay, J S Reis-Filho, J Burn, J Langtry, M Sieber-Blum, C J Lord, A Ashworth. Oncogene 2011
100
Bcl2 and ROS1 expression in human meningiomas: an analysis with respect to histological subtype.
V Girish, N Sachdeva, R W Minz, B Radotra, S N Mathuria, S K Arora. Indian J Pathol Microbiol 2005
V Girish, N Sachdeva, R W Minz, B Radotra, S N Mathuria, S K Arora. Indian J Pathol Microbiol 2005
100
100
Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib.
Neil Parrott, Cordula Stillhart, Marc Lindenberg, Bjoern Wagner, Karey Kowalski, Elena Guerini, Nassim Djebli, Georgina Meneses-Lorente. AAPS J 2020
Neil Parrott, Cordula Stillhart, Marc Lindenberg, Bjoern Wagner, Karey Kowalski, Elena Guerini, Nassim Djebli, Georgina Meneses-Lorente. AAPS J 2020
100
In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening.
Xiao Hua Ma, Zhe Shi, Chunyan Tan, Yuyang Jiang, Mei Lin Go, Boon Chuan Low, Yu Zong Chen. Pharm Res 2010
Xiao Hua Ma, Zhe Shi, Chunyan Tan, Yuyang Jiang, Mei Lin Go, Boon Chuan Low, Yu Zong Chen. Pharm Res 2010
100
Pharmacophore modeling and applications in drug discovery: challenges and recent advances.
Sheng-Yong Yang. Drug Discov Today 2010
Sheng-Yong Yang. Drug Discov Today 2010
100
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
A Drilon, G Li, S Dogan, M Gounder, R Shen, M Arcila, L Wang, D M Hyman, J Hechtman, G Wei,[...]. Ann Oncol 2016
A Drilon, G Li, S Dogan, M Gounder, R Shen, M Arcila, L Wang, D M Hyman, J Hechtman, G Wei,[...]. Ann Oncol 2016
100
Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
Monika A Davare, Jacob J Henderson, Anupriya Agarwal, Jacob P Wagner, Sudarshan R Iyer, Nameeta Shah, Randy Woltjer, Romel Somwar, Stephen W Gilheeney, Ana DeCarvalo,[...]. Clin Cancer Res 2018
Monika A Davare, Jacob J Henderson, Anupriya Agarwal, Jacob P Wagner, Sudarshan R Iyer, Nameeta Shah, Randy Woltjer, Romel Somwar, Stephen W Gilheeney, Ana DeCarvalo,[...]. Clin Cancer Res 2018
100
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima,[...]. Nat Commun 2019
Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima,[...]. Nat Commun 2019
100
Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Holly L Pacenta, Margaret E Macy. Drug Des Devel Ther 2018
Holly L Pacenta, Margaret E Macy. Drug Des Devel Ther 2018
100
trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development.
R Klein, L F Parada, F Coulier, M Barbacid. EMBO J 1989
R Klein, L F Parada, F Coulier, M Barbacid. EMBO J 1989
100
Next-generation phenotypic screening.
Scott J Warchal, Asier Unciti-Broceta, Neil O Carragher. Future Med Chem 2016
Scott J Warchal, Asier Unciti-Broceta, Neil O Carragher. Future Med Chem 2016
100
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
S W Morris, M N Kirstein, M B Valentine, K G Dittmer, D N Shapiro, D L Saltman, A T Look. Science 1994
S W Morris, M N Kirstein, M B Valentine, K G Dittmer, D N Shapiro, D L Saltman, A T Look. Science 1994
100
Expression and localization of c-ros oncogene along the human excurrent duct.
Christine Légaré, Robert Sullivan. Mol Hum Reprod 2004
Christine Légaré, Robert Sullivan. Mol Hum Reprod 2004
100
The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer.
Jaime Acquaviva, Ricky Wong, Al Charest. Biochim Biophys Acta 2009
Jaime Acquaviva, Ricky Wong, Al Charest. Biochim Biophys Acta 2009
100
Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion.
Clare Keddy, Tanaya Neff, Jianya Huan, Joshua P Nickerson, Catherine Z Beach, Yassmine Akkari, Jianling Ji, Stephen Moore, Kellie J Nazemi, Christopher L Corless,[...]. Cold Spring Harb Mol Case Stud 2021
Clare Keddy, Tanaya Neff, Jianya Huan, Joshua P Nickerson, Catherine Z Beach, Yassmine Akkari, Jianling Ji, Stephen Moore, Kellie J Nazemi, Christopher L Corless,[...]. Cold Spring Harb Mol Case Stud 2021
100
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.
Christine M Lovly, Johannes M Heuckmann, Elisa de Stanchina, Heidi Chen, Roman K Thomas, Chris Liang, William Pao. Cancer Res 2011
Christine M Lovly, Johannes M Heuckmann, Elisa de Stanchina, Heidi Chen, Roman K Thomas, Chris Liang, William Pao. Cancer Res 2011
100
Expression of the ROS1 oncogene for tyrosine receptor kinase in adult human meningiomas.
J F Zhao, S Sharma. Cancer Genet Cytogenet 1995
J F Zhao, S Sharma. Cancer Genet Cytogenet 1995
100
From magic bullets to designed multiple ligands.
Richard Morphy, Corinne Kay, Zoran Rankovic. Drug Discov Today 2004
Richard Morphy, Corinne Kay, Zoran Rankovic. Drug Discov Today 2004
100
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
100
Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report.
Kensuke Suzuki, Hiroshi Harada, Masayuki Takeda, Chisato Ohe, Yoshiko Uemura, Akihiko Kawahara, Shunsuke Sawada, Akira Kanda, Bhaswati Sengupta, Hiroshi Iwai. BMC Med Genomics 2022
Kensuke Suzuki, Hiroshi Harada, Masayuki Takeda, Chisato Ohe, Yoshiko Uemura, Akihiko Kawahara, Shunsuke Sawada, Akira Kanda, Bhaswati Sengupta, Hiroshi Iwai. BMC Med Genomics 2022
100
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.